Barclays PLC Emergent Bio Solutions Inc. Transaction History

Barclays PLC

$357 Billion
Q4 2024

A detailed history of Barclays PLC transactions in Emergent Bio Solutions Inc. stock. As of the latest transaction made, Barclays PLC holds 94,523 shares of EBS stock, worth $545,397. This represents 0.0% of its overall portfolio holdings.

Number of Shares

94,523

Previous 39,308 140.47%

Holding current value

$545,397

Previous $329,000 174.77%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$7.72 - $11.97 $426,259 - $660,923	55,215 Added 140.47%	94,523 $904,000
Q3 2024 Nov 15, 2024	BUY	$5.72 - $14.77 $176,130 - $454,797	30,792 Added 361.58%	39,308 $329,000
Q2 2024 Aug 14, 2024	SELL	$1.86 - $6.98 $55,219 - $207,222	-29,688 Reduced 77.71%	8,516 $58,000
Q1 2024 May 15, 2024	SELL	$1.5 - $3.41 $152,086 - $345,743	-101,391 Reduced 72.63%	38,204 $97,000
Q4 2023 Feb 15, 2024	BUY	$1.82 - $3.16 $47,667 - $82,763	26,191 Added 23.1%	139,595 $336,000
Q3 2023 Nov 07, 2023	SELL	$3.17 - $7.91 $538,909 - $1.34 Million	-170,003 Reduced 59.99%	113,404 $385,000
Q2 2023 Aug 03, 2023	BUY	$7.35 - $13.21 $928,937 - $1.67 Million	126,386 Added 80.49%	283,407 $2.08 Million
Q1 2023 May 04, 2023	SELL	$7.79 - $16.29 $634,059 - $1.33 Million	-81,394 Reduced 34.14%	157,021 $1.63 Million
Q4 2022 Feb 13, 2023	BUY	$11.0 - $21.45 $750,475 - $1.46 Million	68,225 Added 40.09%	238,415 $2.82 Million
Q3 2022 Nov 03, 2022	BUY	$20.09 - $35.8 $2.95 Million - $5.26 Million	146,857 Added 629.4%	170,190 $3.57 Million
Q2 2022 Aug 12, 2022	SELL	$27.42 - $43.63 $1.13 Million - $1.8 Million	-41,222 Reduced 63.86%	23,333 $724,000
Q1 2022 May 16, 2022	BUY	$36.48 - $52.22 $24,952 - $35,718	684 Added 1.07%	64,555 $2.65 Million
Q4 2021 Feb 14, 2022	BUY	$33.11 - $55.01 $563,730 - $936,600	17,026 Added 36.35%	63,871 $2.78 Million
Q3 2021 Nov 09, 2021	BUY	$50.07 - $66.05 $141,047 - $186,062	2,817 Added 6.4%	46,845 $2.35 Million
Q2 2021 Aug 13, 2021	SELL	$56.61 - $80.46 $493,922 - $702,013	-8,725 Reduced 16.54%	44,028 $2.77 Million
Q1 2021 May 13, 2021	BUY	$86.23 - $125.19 $998,198 - $1.45 Million	11,576 Added 28.11%	52,753 $4.9 Million
Q4 2020 Feb 11, 2021	SELL	$79.17 - $111.47 $2.1 Million - $2.95 Million	-26,485 Reduced 39.14%	41,177 $3.69 Million
Q3 2020 Nov 12, 2020	SELL	$81.91 - $134.94 $315,926 - $520,463	-3,857 Reduced 5.39%	67,662 $6.99 Million
Q2 2020 Aug 12, 2020	SELL	$54.33 - $89.52 $3.06 Million - $5.04 Million	-56,272 Reduced 44.03%	71,519 $5.66 Million
Q1 2020 May 13, 2020	SELL	$49.34 - $68.76 $2.84 Million - $3.95 Million	-57,468 Reduced 31.02%	127,791 $7.39 Million
Q4 2019 Feb 10, 2020	BUY	$51.21 - $59.06 $6.57 Million - $7.58 Million	128,299 Added 225.24%	185,259 $10 Million
Q3 2019 Nov 14, 2019	SELL	$40.6 - $57.2 $257,322 - $362,533	-6,338 Reduced 10.01%	56,960 $2.98 Million
Q2 2019 Aug 14, 2019	BUY	$39.92 - $53.86 $926,183 - $1.25 Million	23,201 Added 57.86%	63,298 $3.06 Million
Q1 2019 May 15, 2019	BUY	$48.23 - $66.16 $649,851 - $891,439	13,474 Added 50.61%	40,097 $2.03 Million
Q4 2018 Feb 14, 2019	SELL	$55.63 - $73.24 $1.11 Million - $1.46 Million	-19,959 Reduced 42.85%	26,623 $1.58 Million
Q3 2018 Nov 14, 2018	BUY	$52.05 - $66.51 $1.72 Million - $2.19 Million	32,973 Added 242.29%	46,582 $3.07 Million
Q2 2018 Aug 14, 2018	SELL	$48.33 - $55.64 $554,248 - $638,079	-11,468 Reduced 45.73%	13,609 $687,000
Q1 2018 May 15, 2018	BUY	$44.44 - $54.39 $116,477 - $142,556	2,621 Added 11.67%	25,077 $1.32 Million
Q4 2017 Feb 14, 2018	BUY	$37.77 - $47.75 $336,153 - $424,975	8,900 Added 65.65%	22,456 $1.04 Million
Q3 2017 Nov 14, 2017	BUY	$34.14 - $40.45 $462,801 - $548,340	13,556	13,556 $548,000

Others Institutions Holding EBS

# of Institutions

174

Shares Held

36.8M

Call Options Held

336K

Put Options Held

203K

View Full List

About Emergent BioSolutions Inc.

Ticker EBS
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,861,500
Market Cap $288M
Description
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emergi...

More about EBS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account